CSPG4 and thyroid gland carcinoma: To determine which RTKs participate in NG2-mediated resistance of BRAF-mutant thyroid cancer cells to BRAF inhibitor, we established NG2-knockout 8505 C cell- and control cell-derived xenograft mouse models, and treated them with PLX4720 (20 mg/kg).